Causal Evaluation of Laboratory Markers in Type 2 Diabetes on Cancer and Vascular Diseases Using Various Mendelian Randomization Tools - Jin, Heejin; Lee, Sanghun; Won, Sungho (medRxiv, 2020)
Multiple studies have demonstrated the effects of type 2 diabetes (T2D) on various human diseases; however, most of these were observational epidemiological studies that suffered from many potential biases including reported confounding and reverse causations. In this article, we investigated whether cancer and vascular disease can be affected by T2D-related traits, including fasting plasma glucose (FPG), 2-h postprandial plasma glucose (2h-PG), and glycated hemoglobin A1c (HbA1c) levels, by using Mendelian randomization (MR). The summary statistics for FPG, 2h-PG, and HbA1c were obtained through meta-analyses of large-scale genome-wide association studies that included data from 133,010 non-diabetic individuals from collaborating Meta-Analysis of Glucose and Insulin related traits Consortium studies. Thereafter, based on the statistical assumptions for MR analyses, the most reliable approaches including inverse-variance-weighted (IVW), MR-Egger, MR-Egger with a simulation extrapolation (SIMEX), weighted median and MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) methods were applied to identify traits affected by FPG, 2h-PG, and HbA1c. We found that coronary artery disease is affected by FPG, as per the IVW [log odds ratio (logOR): 0.21; P=0.012], MR-Egger (SIMEX) (logOR: 0.22; P=0.014), MR-PRESSO (logOR: 0.18; P=0.045), and weighted median (logOR: 0.29; P<0.001) methods, but not as per the MR-Egger (logOR: 0.13; P=0.426) approach. Furthermore, low-density lipoprotein cholesterol levels are affected by HbA1c, as per the IVW (beta (B): 0.23; P=0.015), MR-Egger (B: 0.45; P=0.046), MR-Egger (SIMEX) (B: 0.27; P=0.007), MR-PRESSO (B; 0.14; P=0.010), and the weighted median (B: 0.15; P=0.012) methods. Further studies of the associated biological mechanisms are required to validate and understand the disease-specific differences identified in the TD2-related causal effects of each trait.Competing Interest StatementWon is employed by RexSoft Corp. Remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflict of interest.Funding StatementThis study was supported by the National Research Foundation of Korea (2017M3A9F3046543).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research consider data which has already been published and is exempt from IRB oversight.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe summary statistics for T2D-related trait were obtained through large-scale genome-wide association (GWAS) meta-analyses of 133,010 non-diabetic individuals from the collaborating studies within the Meta-Analysis of Glucose and Insulin related traits Consortium (MAGIC) https://www.magicinvestigators.org/